Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 65.8% in August

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 96,600 shares, a decrease of 65.8% from the August 15th total of 282,600 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 264,700 shares, the short-interest ratio is currently 0.4 days.

Monopar Therapeutics Trading Up 4.3 %

Shares of NASDAQ MNPR traded up $0.02 during mid-day trading on Wednesday, hitting $0.61. The company had a trading volume of 15,897 shares, compared to its average volume of 205,866. The company has a market capitalization of $8.64 million, a PE ratio of -0.77 and a beta of 0.93. The firm has a 50-day simple moving average of $0.72 and a two-hundred day simple moving average of $1.20. Monopar Therapeutics has a one year low of $0.57 and a one year high of $4.88.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Sell-side analysts expect that Monopar Therapeutics will post -0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

A hedge fund recently raised its stake in Monopar Therapeutics stock. UBS Group AG increased its holdings in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 529.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,561 shares of the company’s stock after buying an additional 16,455 shares during the period. UBS Group AG owned 0.16% of Monopar Therapeutics worth $45,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 6.18% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.